ArticleCell2017
HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis.
Abstract read
In one paragraph
Article in Cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 165 papers.
0numbers the graph read from it
0cells of the map it votes in
165citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
165 citing papers in PubMed.
- Human papillomavirus and the landscape of secondary genetic alterations in oral cancers.Genome research · 2019Trial
- Article
- Improving cervical screening risk stratification through extended human papillomavirus genotyping and age-specific data.European journal of public health · 2026Article
- Longitudinal analysis of high-risk HPV infections reveals within-host viral genome changes over time.PLoS pathogens · 2026Article
- Genetic Variation of HPV53 and the Identification of T-Cell Epitopes.Microorganisms · 2026Article
- Covalent inhibitors of human papillomavirus type 16 E6 protein restore p53 function and suppress growth of HPV-driven tumors in vivo.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Article
- HPV16 genetic variation provides evidence of positive natural selection driven by HLA class I.Nature communications · 2026Article
- Genetic Variability and Conserved T-Cell Epitope Prediction of the HPV16 E1 Protein in Cervix Samples from Peru.Pathogens (Basel, Switzerland) · 2026Article
- Characterization of patient-derived HPV16 E6 and E7 variant alleles.Journal of virology · 2026Article
- Human papillomavirus16 E7 enhances cell stemness by regulating the APC2/SPIN4/β-catenin axis in cervical cancer.Oncogenesis · 2026Article
- Long-term human papillomavirus genotype-specific risk of cervical high-grade intraepithelial lesion and cancer-By age group and triage cytology.International journal of cancer · 2026Article
- A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial).Frontiers in oncology · 2026Article
- AI-driven radiogenomics in gynecologic oncology: from radiological digital biopsy to a new paradigm in precision therapy.Frontiers in oncology · 2026Review
- Phenotypic effect of the mutations H78Y and L83V in the E6 protein of human papillomavirus.Archives of virology · 2025Article
- HPV16 E6 and E7 Genetic Variability in Oral and Anal Samples from HIV-Positive MSM.Pathogens (Basel, Switzerland) · 2025Article
- Albumin-recruiting lipid nanoparticle potentiates the safety and efficacy of mRNA vaccines by avoiding liver accumulation.Nature materials · 2025Article
- The actin nucleation promoting factor WASH facilitates clathrin-independent endocytosis of human papillomaviruses.EMBO reports · 2025Article
- Whole-genome sequencing of 1,083 HPV45 cases and controls identifies genetic variants associated with glandular cervical lesions.International journal of cancer · 2025Article
- HPV-driven cancers: a looming threat and the potential of CRISPR/Cas9 for targeted therapy.Virology journal · 2025Review
105 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
32 authors.
Lisa MirabelloDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA. Electronic address: mirabellol@mail.nih.gov.
Meredith YeagerDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA; Cancer Genomics Research Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, USA.
Kai YuDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
Gary M CliffordInfections and Cancer Epidemiology Group, International Agency for Research on Cancer 150, Cours Albert Thomas, 69372 Lyon Cedex 08, France.
Yanzi XiaoDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
Bin ZhuDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
Michael CullenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA; Cancer Genomics Research Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, USA.
Joseph F BolandDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA; Cancer Genomics Research Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, USA.
Nicolas WentzensenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
Chase W NelsonSackler Institute for Comparative Genomics, American Museum of Natural History, New York City, NY, USA.
Tina Raine-BennettWomen's Health Research Institute, Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
Zigui ChenDepartment of Microbiology, The Chinese University of Hong Kong, Shatin, Hong Kong.
Sara BassDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA; Cancer Genomics Research Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, USA.
Lei SongDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA; Cancer Genomics Research Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, USA.
Qi YangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA; Cancer Genomics Research Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, USA.
Mia SteinbergDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA; Cancer Genomics Research Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, USA.
Laurie BurdettDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA; Cancer Genomics Research Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, USA.
Michael DeanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
David RobersonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA; Cancer Genomics Research Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, USA.
Jason MitchellDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA; Cancer Genomics Research Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, USA.
Thomas LoreyRegional Laboratory, Kaiser Permanente Northern California, Oakland, CA, USA.
Silvia FranceschiInfections and Cancer Epidemiology Group, International Agency for Research on Cancer 150, Cours Albert Thomas, 69372 Lyon Cedex 08, France.
Philip E CastleDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA.
Joan WalkerUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Rosemary ZunaUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Aimée R KreimerDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
Daniel C BeachlerDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA; HealthCore Inc., Safety and Epidemiology, Wilmington, DE, USA.
Allan HildesheimDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
Paula GonzalezAgencia Costarricense de Investigaciones Biomédicas (ACIB), former Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, Guanacaste, Costa Rica.
Carolina PorrasAgencia Costarricense de Investigaciones Biomédicas (ACIB), former Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, Guanacaste, Costa Rica.
Robert D BurkDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA; Departments of Pediatrics, Microbiology and Immunology, and Obstetrics & Gynecology and Women's Health, Albert Einstein College of Medicine, Bronx, NY, USA.
Mark SchiffmanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
Funding
WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI THOMAS E ROHAN · 1985 to 2026
$111.2MHuman Papillomavirus (HPV) Genomics ProjectZIACP010228 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MIRABELLO, LISA · 2016 to 2025
$9.9MPERSISTENT HUMAN PAPILLOMAVIRUS IN WOMEN AT RISK FOR CERVIX CANCERU01CA078527 · NCI · YESHIVA UNIVERSITY · PI BURK, ROBERT D · 2003 to 2018
$8.6MPERSISTENT HPV IN WOMEN AT RISK FOR CERVIX CANCERR01CA078527 · NCI · YESHIVA UNIVERSITY · PI BURK, ROBERT D. · 1998 to 2002
$1.5MCCR NIH HHS HHSN261200800001CIntramural NIH HHS ZIA CP010228NCI NIH HHS HHSN261200800001ENCI NIH HHS P30 CA013330NCI NIH HHS R01 CA078527NCI NIH HHS U01 CA078527World Health Organization 001
Abstract
Although most cervical human papillomavirus type 16 (HPV16) infections become undetectable within 1-2 years, persistent HPV16 causes half of all cervical cancers. We used a novel HPV whole-genome sequencing technique to evaluate an exceptionally large collection of 5,570 HPV16-infected case-control samples to determine whether viral genetic variation influences risk of cervical precancer and cancer. We observed thousands of unique HPV16 genomes; very few women shared the identical HPV16 sequence, which should stimulate a careful re-evaluation of the clinical implications of HPV mutation rates, transmission, clearance, and persistence. In case-control analyses, HPV16 in the controls had significantly more amino acid changing variants throughout the genome. Strikingly, E7 was devoid of variants in precancers/cancers compared to higher levels in the controls; we confirmed this in cancers from around the world. Strict conservation of the 98 amino acids of E7, which disrupts Rb function, is critical for HPV16 carcinogenesis, presenting a highly specific target for etiologic and therapeutic research.
Indexed as
AdultAlphapapillomavirusCarcinomaCase-Control StudiesFemaleGenome, ViralHumansMiddle AgedPapillomavirus E7 ProteinsPapillomavirus InfectionsPolymorphism, Single NucleotideUterine Cervical NeoplasmsYoung Adultoncogene protein E7, Human papillomavirus type 16Papillomavirus E7 Proteinscervical carcinogenesisE7 geneHPV16HPV epidemiologyHPV genomics
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.